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ABSTRACT
We believe the prevention of infection-related adverse pregnancy outcome is the most important
focus for obstetricians today. An emphasis upon immunization of susceptible women, prevention
of transmissible disease by modification of patient behavior, and identification and treatment of
silent infections should become standards of practice. This will require educational initiatives for
physicians and their patients as well as continued clinical trials to determine costs and effectiveness.
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his is an uncomfortable topic for obstetricians.
It requires a change in practice priorities. As a
specialty, we have focused upon operative skills
plus the recognition and treatment of disease.
Moving our priorities forward to prevention will be
difficult because it represents an abrupt change in
care. What are our standards today? In middle class
America, the newly sexually active teenager
switches her physician provider from the pediatri-
cian to the obstetrician. Currently, the screening
for this young woman is a Papanicolaou (Pap)
smear and prevention is limited to a prescription
for an oral contraceptive. This protects against an
unwanted pregnancy, but offers no protection
against sexually transmitted diseases. For urban
poor women, no preventive care is available. The
focus is on pathology. We treat urban poor teenag-
ers with an unwanted pregnancy or symptomatic
pelvic inflammatory disease. This is a narrow and
unacceptable scope of practice.
An outline for infection-related adverse preg-
nancy outcomes has been the mnemonic TORCH,
in which the significant pathogens for the fetus
have been identified. We would like to expand this
to STORCHs for the purposes of this discussion of
prevention (see Table 1). The focus will be di-
rected toward three strategies of prevention: vac-
cine administration, preventive counseling to
achieve maternal behavior modification, and treat-
ment of silent infections. All of these strategies
require the use of screening laboratory studies to
determine the risks in asymptomatic patients. This
requires, on the part of the obstetrician, knowledge
and understanding of laboratory studies, many of
which are new.
VACCINES
An awareness of immunization standards is impor-
tant for the obstetrician. In the United States, we
are the primary care physician for most women dur-
ing their childbearing years. We need to know the
needs of our patients and the status of vaccines,
i.e., are they live virus preparations or not. For the
pregnant woman, live virus vaccines should be
avoided.
Tetanus-Diphtheria
This is a toxoid preparation, not a live virus. Ad-
ministration to women in their childbearing years
maintains the protection afforded by childhood im-
munization. Tetanus is an uncommon disease in
*Correspondence to: Dr. William J. Ledger, Department of Obstetrics and Gynecology, New York Hospital-Cornell Medical
Center, 525 East 68th Street, J-130, New York, NY 10021.
Received October 1997
Accepted 21 October 1997PREVENTION OF INFECTION IN PREGNANCY LEDGER AND SKUPSKI
TABLE I. Storchs
s Syphilis
T Toxoplasmosis
O Other
Bacterial vaginosis
Trichomonas vaginalis
Group B streptococcus
Escherichia coli
Ureaplasma urealyticum
Hemophilus influenzae
Varicella
Listeria monocytogenes
R Rubella
C Cytomegalovirus
H Herpes
Human immunodeficiency virus
Hepatitis B
Human papilloma virus
Human parvovirus
the United States, but it still occurs, particularly
among the elderly, and it is preventable. Diphthe-
ria has become a major health problem in Eastern
Europe, particularly in some of the new countries
that have split off from the old United Soviet So-
cialist Republic. Pregnant women traveling to that
area or who have exposure to Eastern European
immigrants are at risk for this disease (Weissen-
bacher, personal communication).
Varicella
Varicella is a serious disease for a pregnant woman.
It can result in a pneumonia that is fatalz and trans-
placental transmission can result in serious fetal
problems.3 A live virus varicella vaccine has been
approved in the United States. Pregnant women
should be tested for their susceptibility to this in-
fection. Susceptible women can be immunized
postpartum with two injections, month apart.
Rubella
Rubella represents a success story for preventive
care by obstetricians. The introduction of this live
virus vaccine in the late 1960s resulted in a dra-
matic decline in the number of rubella and con-
genital rubella cases in the United States.4 The
current standard of obstetrical practice involves
screening for rubella antibody and immunizing sus-
ceptible women postpartum. These patients
should be warned that adult women can develop a
transient arthritis after receiving this live virus im-
munization,s
Hepatitis B
The obstetrical record of prevention against hepa-
titis B is lacking. Currently, obstetricians screen
pregnant women for the presence of hepatitis B
antigen and prepare the pediatrician for treatment
of the newborn of the antigen-positive mother with
immunoglobulins and hepatitis B vaccine.6 This
strategy to detect a silent infection is commend-
able, but it is an incomplete approach to the prob-
lem. Hepatitis B is a serious infection, which can be
sexually transmitted, and it is preventable. The
vaccine contains surface antigens, not live virus,
and can be administered to mothers at high risk for
hepatitis B acquisition during pregnancy.7 We be-
lieve all susceptible pregnant women should be
immunized postpartum. This requires antibody
screening for susceptibility and a three-injection
immunization schedule given over 6 months in the
postpartum period.
Pneumococcal Pneumonia
Pneumococcal pneumonia can be a serious life-
threatening disease. This is particularly true for
high risk populations, which include patients over
the age of 65 years, and those women with immune
deficiencies, with sickle cell disease, or a prior his-
tory of a splenectomy. In the past, there was a total
physician reliance upon antibiotics, because Strep-
tococcus pneumoniae was so susceptible to antibiot-
ics. The recent emergence of ever increasing num-
bers of penicillin resistant S. pneumoniae strains8
puts this strategy in question. For pregnant
women, pneumococcal vaccine should be offered
to human immunodeficiency virus (HIV)-positive
patients, those with sickle cell disease, and those
with a previous history of a splenectomy.
PREVENTION
Prevention is an unfamiliar therapeutic strategy for
obstetricians. It requires knowledge of the natural
course of infection, antibody testing for suscepti-
bility, and instruction to avoid disease acquisition
during pregnancy.
Toxoplasmosis
For some reason, screening for toxoplasmosis is not
recommended for American obstetricians.9 This is
in contrast to Belgium1 and France,1 where
screening for toxoplasmosis is not only accepted,
but mandated. Arguments in the United States
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TABLE 2. Recommendations for the toxoplasmosis
antibody-negative pregnant patient
Patients should be advised not to eat raw or undercooked
meat, particularly pork, lamb, or venison. Specifically, meat
should be cooked to an internal temperature of 150F
(65.5C); meat cooked until no longer pink inside generally
has an internal temperature of 165F (73.8C).
Patients should be advised to wash their hands after contact
with raw meat and after gardening or contact with soil; in
addition, they should wash fruit and vegetables well before
eating them raw.
If the patient owns a cat, someone else should change the
litter box daily; alternatively, the patient should wash her
hands thoroughly after changing the litter box. Patients
should be encouraged to keep their cats inside and not to
adopt or handle stray cats.
TABLE 3. Recommendations for the CMV
antibody-negative pregnant patient
Patients should be advised that CMV is shed in semen,
cervical secretions, and saliva. Latex condoms should be
used during sexual contact, if the patient is not in a
monogamous relationship.
Providers of child care or parents of children in the child
care center should be informed that they are at increased
risk of acquiring CMV infection. The risk of CMV infection
can be diminished by avoiding mouth-to-mouth kissing.
Frequent hand washing should be done, particularly after
changing diapers.
If a blood transfusion is needed, these patients should
receive only CMV antibody-negative blood or
leukocyte-reduced cellular blood products in
non-emergency situations.
against toxoplasmosis screening are based upon
cost effectiveness. The patient at risk is the sus-
ceptible woman who acquires the infection during
pregnancy. Although acquisition of toxoplasmosis
during pregnancy is uncommon, approximately
90% of those who get infected during pregnancy
have no symptoms and thus are unaware of the
infection, le This makes a strong argument for uni-
versal screening of pregnant patients. Suggestions
that most mothers who become infected will seek
medical care9 fly in the face of reported reality, lz
This is an uncommon infection. One study of preg-
nant women in New York City reported 6 toxoplas-
mosis infections among 4,048 pregnant women
(1.5/1,000). 13 Not every newborn exposed to this
pathogen will have persistent infection at birth. In
a study in Massachusetts, only 52 of 635,000 infants
delivered had congenital infection. 14 That is less
than in 10,000 births. However, this is a serious
infection for the newborn, it is treatable, and only
2 of the 52 infected infants were detected on clini-
cal grounds. Without universal screening, 50 would
have been denied early treatment. Despite the in-
frequency, we believe toxoplasmosis screening is
indicated. For susceptible women, a series of pre-
ventive guidelines can be given (see Table 2).s A
similar preventive program in Belgium has signifi-
cantly reduced maternal acquisition of toxoplasmo-
sis during pregnancy.1
Cytomegalovirus (CMV)
CMV presents a different set of circumstances. It is
a much more common infection and most authori-
ties think it is the most frequent pathogen involved
in newborn morbidity. A recent publication from
the Centers for Disease Control (CDC) estimated
that 30,000-40,000 infants are infected each year
with CMV and 9,000 of these infants suffer perma-
nent sequelae.
6 Other evaluations indicate that
the most frequent and serious newborn infections
occur in susceptible women who acquire their first
infection during pregnancy. 17 The presence of an-
tibody offers protection to the newborn. American
obstetricians have not offered screening for CMV
because no effective antiviral therapy has surfaced.
This is a short-sighted approach. Antibody screen-
ing should be done in pregnant women to deter-
mine susceptibility. If susceptible, the pregnant
women should have three options presented to her
(see Table 3).s For this virus, there are a wide
variety of risks. CMV is a sexually transmitted dis-
ease. A sexually active pregnant woman who is not
in a monogamous relationship should require her
male sexual partner to wear a condom. This re-
quires attitudinal changes by both the obstetrician
and the pregnant woman. The condom in this situ-
ation is not to prevent pregnancy, but to lower the
risk of acquiring a sexually transmitted disease.
Small children in a group setting such as a day care
center are frequently infected with CMV and are
asymptomatic.
18 They shed large amounts of virus
their saliva and urine. Susceptible women should
avoid "sloppy" kisses with these children and
should wash their hands if they have to change a
diaper. Finally, for the rare occasions when a sus-
ceptible pregnant woman needs a blood transfu-
sion, the donated blood should be CMV antibody
negative. If this is not possible, leukocyte depleted
blood should be given to lower the risk of CMV
acquisition. 19 None of these preventive measures
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should be difficult to institute. The starting point
in this preventive strategy is antibody screening to
determine susceptibility.
HIV
HIV is an increasingly important problem world-
wide for obstetricians because of its frequency and
serious long-term implications. In the United
States, the number of women infected by hetero-
sexual contact continues to increase and the result
is a continuing increase in the number of women
developing acquired immunodeficiency syndrome
(AIDS).2 Screening to determine susceptibility is
important. If these susceptible women are intrave-
nous drug users, they must be counseled to avoid
needle sharing. If they are not in a monogamous
sexual relationship or the HIV antibody status .of
their partner is not known, they should be coun-
seled to require condom use. Again, this is for dis-
ease prevention, not contraception.
Herpes
This is a developing new story for obstetricians. In
the past decade, a number of studies have docu-
mented the fact that herpes simplex virus (HSV)
acquisition can occur without symptomatology. 21’22
These people can shed virus without symptoms
and infect susceptible sexual partners. For the
pregnant woman, the greatest risk of newborn in-
fection with herpes occurs when the infection is
first acquired shortly before the onset of labor. A
recent study indicates that this acquisition can be
best documented by repeated HSV antibody
screening during pregnancy.23 In this study, only
36% of the women who seroconverted had symp-
toms consistent with herpes infection. This is a
higher incidence of symptoms with virus acquisi-
tion than is seen in the non-pregnant adult popu-
lation,z There are interesting future preventive
strategies for susceptible women. The male of the
herpes susceptible pregnant patient can be tested.
If the male is HSV-1 or HSV-2 antibody positive,
the patient is at risk for herpes acquisition during
pregnancy. Abstinence or the use of a condom dur-
ing the last trimester may lower the risk for such a
patient,z3 Future studies will determine the ben-
efits of such a strategy.
Listeria monocgtogenes
L. monocytogenes is an uncommon cause of newborn
infection, but maternal infection can result in pre-
term labor and delivery with newborn sepsis and
death,z4 Most outbreaks are associated with mater-
nal ingestion of contaminated dairy products. To
avoid this, we advise pregnant women in New York
City to avoid the ingestion of all cheeses that have
not been labeled pasteurized. This includes im-
ported cheeses with a rind as well as feta cheese.
SILENT INFECTION
Screening and treating silent infections are rela-
tively new concepts for the obstetrician. In the
past, we have focused our efforts upon the recog-
nition of the signs and symptoms of a clinical in-
fection, confirming our clinical suspicions with spe-
cific laboratory testing. It is becoming increasingly
clear that many maternal infections that can cause
problems for the mother or fetus are either asymp-
tomatic or cause such minimal symptoms that the
mother to be will not seek medical care. This re-
quires physicians to shift their concerns to screen
asymptomatic women to detect these infections
followed by a treatment strategy. There are a num-
ber of screens that should be regularly employed.
Asymptomatic Bacteriuria
This is a familiar screen for asymptomatic disease
by the obstetrician. A clean voided urine is ob-
tained at the first prenatal visit and those women
with a colony count of 100,000 or greater are
treated. There is good evidence that this strategy
reduces the subsequent incidence of pyelonephri-
tis.zs This has been an effective preventive strat-
egy for obstetricians.
Bacterial Vaginosis (BV)
This is the current infectious disease "hot item"
for obstetricians. BV is manifested by a tremendous
increase in the number of bacteria in the vagina
and many women so detected are asymptomatic.
More important, the Vaginal Infections in Preg-
nancy (VIP) study showed an association with BV
and the delivery of a low birth weight infant,z6 An
optimistic sign is that treatment studies with both
systemic clindamycin27 and metronidazole28 have
been effective in reducing the rates of preterm
births. Vaginal antibiotic preparations which are ef-
fective in the treatment of BV have not resulted in
a lowering of the rate of prematurity,z9, Armed
with this information, a system of screening and
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treatment of those who test positive has been de-
vised.
The diagnosis of BV can be made within min-
utes of the obstetrician-patient contact. Every time
a vaginal examination is done on a pregnant
woman, the following screening tests should be
done. The vaginal pH should be tested to see if it
is alkaline and a drop of vaginal secretion placed on
a drop of dilute potassium hydroxide on a slide and
checked immediately to see if a "fishy" odor ema-
nates. If either of these tests is positive, another
vaginal secretion sample should be placed on a
drop of normal saline on a slide and examined un-
der a microscope. If over 20% of the epithelial cells
are "clue" cells, the diagnosis is confirmed. The
treatment should be with oral metronidazolez8 or
oral clindamycinz7 for at least 7 days. There is one
study from Germany suggesting that va[ginal clin-
damycin treatment given before 14 weeks gesta-
tion lowers the incidence of preterm births in the
treated population (Dennemark, personal c.ommu-
nication). Further studies on this early pregnancy
population will be needed to confirm this observa-
tion. If so, it would simplify the care ofwomen with
BV in the first trimester.
Trichomonas vaginalis
There is increasing interest in the asymptomatic
pregnant patient with T. vaginalis vaginitis. In the
VIP study, the finding of T. vaginalis by a culture
technique was associated with a higher incidence
of preterm labor than was seen with BV.31 Another
recent study using the polymerase chain reaction
(PCR), a more sensitive test than the culture tech-
nique used in the VIP study, found a high inci-
dence of vaginal Trichomonas infection in an urban
poor population with a high incidence of prematu-
rity.3z Further information about the risk of Tricho-
monas for the pregnant patient requires a dual strat-
egy of physician education and prospective study.
Physicians must learn that asymptomatic vaginal
Trichomonas exists and the microscopic examina-
tion of vaginal secretions in saline is not a sensitive
screening test.33 Universal screening needs to be
done on pregnant populations, comparing the preg-
nancy outcomes in PCR and culture-positive pa-
tients. Finally, this infected population needs to be
treated with metronidazole to determine if the pre-
term delivery rate is decreased.
Neisseria gonorrhoege
Pregnant patients can be culture positive for N.
gonorrhoeae without enough symptomatology to
cause them to seek medical attention. If untreated,
these patients have a higher incidence of preterm
labor and delivery.
34 Part of pregnancy care should
involve screening for N. gonorrhoeae. This can be
done with a DNA probe for the incidence if peni-
cillin resistance is high enough that cephalosporins
are now recommended. Treatment with a single
dose of ceftriaxone 250 mg 1M should be ad-
equate.s Antibiotic treatment of the pregnant
woman is also important, because an infected
mother can infect her newborn’s eyes through the
process of labor and delivery.
Chlamydia trachomatis
C. trachomatis is a good example of a bacterial
pathogen that can cause serious problems for both
the mother and the fetus. Women infected with C.
trachomatis have no symptoms or minimal symp-
tomatology that is not severe enough for them to
seek medical care. These symptom-free women, if
infected, have the potential for a series of problems
for the pregnant patient and the fetus. Pregnant
women with C. trachomatis antibodies, evidence of
a past infection, have a higher than expected inci-
dence of spontaneous abortion.6 Among prema-
ture newborns delivered of women colonized with
C. trachomatis, there is a risk of developing a C.
trachomatis pneumonia.7 The newborns of culture-
positive women, both premature and at term, have
the potential for developing ophthalmia neonato-
rum. These serious problems and lack of patient
symptomatology demand universal screening of
pregnant women. PCR should be used because it is
so much more sensitive and specific than the DNA
probes.s PCR-positive women and their sexual
partners should be treated. The CDC recommends
7 days of oral erythromycin therapy for the preg-
nant woman, for it is safe during pregnancy.s The
problem is that erythromycin is poorly tolerated by
most pregnant women. They have enough gastro-
intestinal distress that many of these asymptomatic
women do not complete their course of treatment.
For this reason, we favor the use of amoxicillin in
those pregnant women who are not allergic to peni-
cillin. This antibiotic is better tolerated by the
pregnant recipient and it is effective in eliminating
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the organism.
39 In addition to screening at the time
of the first prenatal visit, we favor another PCR
screen at 35-37 weeks gestation. Term infants born
of infected mothers can develop ophthalmia neo-
natorum from the C. trachomatis and the antibiotic
ophthalmic ointments used in the newborn are not
very effective in curing the infection.4 These cul-
ture-positive women should be treated prior to de-
livery.
Group B Streptococcus
The group B streptococcus is a feared organism by
obstetricians. Vaginal colonization with this organ-
ism which causes no maternal symptomatology can
result in vertical transmission to the fetus with
newborn sepsis and death despite newborn antibi-
otic treatment.41 There is evidence that treatment
of the mother with antibiotics prior to delivery
markedly reduces newborn infectious morbidity
and mortality.42 The problem with any strategy of
antibiotic prophylaxis is the selection of the mother
at risk for newborn group B streptococcal infection.
Much is known about maternal colonization and
newborn infections with the group B streptococcus.
Vaginal colonization with the group B streptococ-
cus is not a constant. Women colonized in the first,
second, or third trimester may not be culture posi-
tive at the time of delivery. Alternatively, women
culture negative at the first, second, or third trimes-
ter vaginal culture screening may be culture posi-
tive at the time of delivery. In one study, only 51%
of women culture positive in the first trimester re-
mained culture positive at the time of delivery.43
This raises natural concerns about preventive strat-
egies using antepartum cultures. Some women who
are culture positive with an antepartum screen will
be negative at the time of birth and some women
who are culture positive at the time of delivery will
not be detected at the time of the antepartum
screen. Rapid screening for the group B streptococ-
cus would obviate this problem, but the systems
studied to date have not been sensitive or spe-
cific.44 This is not an acceptable option at present.
Another problem is the discrepancy between the
incidence of maternal colonization and newborn in-
fection. This varies between 1:204s and 1:102,46
with the highest incidence of newborn problems
seen in those women who deliver premature in-
fants. This means many mothers will be treated to
prevent one case of newborn sepsis. No one rec-
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ommends treating antepartum culture-positive pa-
tients with antibiotics, even though there is an as-
sociation with first trimester group B streptococcus
colonization and preterm premature rupture of the
membranes and preterm delivery.47 There are two
major reasons for this. This antibiotic intervention
has not proved successful in lowering the prema-
ture delivery rate48 and systemic antibiotic treat-
ment has not been effective in the persistent eradi-
cation of the group B streptococcus from the vagina
of these women.49 Finally, there is the question of
the selection of pregnant women to receive antibi-
otic prophylaxis in labor. The CDC has suggested
two strategies for the patient who is not penicillin
allergic; they recommend penicillin G with ampi-
cillin as an alternative,s There is controversy sur-
rounding both of these choices. Penicillin G has a
narrow range of antibacterial activity. For the ob-
stetrician concerned about other organisms which
cause newborn infection with some frequency such
as Escherichia coli, Hemophilus influenzae, Listeria
monocytogenes, Ureaplasma urealyticum, and C. tracho-
matis are not covered. On the positive side, wide-
spread use of this narrow spectrum antibiotic
should not have a major impact on the bacterial
flora found on a labor and delivery floor. Many
obstetricians favor ampicillin, because its wider
spectrum of activity means that some strains of E.
co/i, H. influenzae, and L. monocytogenes will be cov-
ered as well as the group B streptococcus. This
widespread use of a broader spectrum antibiotic
has a cost. There will be a greater impact upon the
antibiotic flora of an obstetrical service and there
already has been one report of an increase in the
number of gram-negative aerobic infections in the
newborn when this ampicillin prophylaxis was em-
ployed,sl There are important considerations to be
kept in mind when a preventive regimen is pro-
posed. All antibiotic intervention regimens have
the capability of lowering the incidence of group B
streptococcal disease,s2 All are different in their
technique of selecting mothers at risk (see Table 4)
and none is 100% successful in preventing group B
streptococcal newborn disease,s2 Intrapartum anti-
biotic administration to the mother will not prevent
all cases. There have been instances in which
mothers given antibiotics when they were admitted
in labor still have delivered infants with group B
sepsis and death due to this infection,s’s2
All of this is prologue to the current CDC rec-
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TABLE 4. Strategies for the prevention of early onset neonatal group B streptococcal infection
Strategy Screening Treatment
None None
2 None All
3 None All high risk (HR)
4 Culture at 28 weeks All culture positive (CP)
5 Culture at 28 weeks All (CP) (HR)
6 Culture at 28 weeks All (CP) (HR)
7 Culture at 36 weeks All preterm, all (CP)
8 Culture at 36 weeks All preterrn, all (CP) (HR)
9 All rapid tests (RT) in labor All (RT) positive
0 (RT) (HR)in labor All (RT) positive
(RT) low risk (LR) in labor All (HR), all (RT) positive
2 Culture at 28 weeks; (RT) culture negative (HR) All (HR), (RT) positive
3 Culture at 28 weeks; (RT) all culture negative All (CP), all (RT) positive
4 Culture at 28 weeks; (RT) (LR) (CP) All (HR), all (RT) positive
5 Culture at 28 weeks; (RT) culture negative (LR) All (HR), all low risk (CP), (RT) positive
6 Culture at 28 weeks; (RT) (LR) (CR) (CP) (HR), (RT) positive
7 Culture at 28 weeks; (RT) (LR) (CP); (RT) (HR) culture negative CP (HR), (RT) positive
8 Culture at 28 weeks; (RT) all. (LR); (RT) culture negative (HR) CP (HR), (RT) positive
9 Culture at 28 weeks; (RT) cttlture negative (HR) All CP, all (RT) positive
ommendations for the control of the group B strep-
tococcus (Figs. 1, 2).50 The recommendations fit
into two main strategies. Each identifies group B
streptococcal risk factors. These include the
woman who has had a previous infant with group B
streptococcal disease, group B streptococcal bacte-
riuria during this pregnancy, and delivery at less
than 37 weeks gestation. The divergence involves
antepartum screening for vaginal carriage of the
group B streptococcus to identify women who
should receive intrapartum antibiotics. This re-
quires medical team sampling of the lower third of
the vagina and the rectum with the same swab and
inserting this specimen in a selective culture me-
dium to increase the yield of positive group B
streptococcus cultures. Whether this increased
group B streptococcal laboratory recovery equates
with improved newborn results is not known. Al-
ternatively, no antepartum cultures are done. Risk
factors identify mothers who will be given intrapar-
tum antibiotics. These include the three previously
mentioned: antepartum asymptomatic bacteriuria
with the group B streptococcus, women with a his-
tory of a previous baby who developed group B
streptococcus sepsis, and those with preterm pre-
mature rupture of the membranes and preterm la-
bor and delivery. There are additional high risk
factors for women beyond 37 weeks. They should
be treated intrapartum with penicillin if they de-
velop a fever during labor, i.e., >38C orally, or
those who will have membranes ruptured > 18 h at
the time of delivery. There have been questions
raised about the <37 week definition of prematu-
rity, the 38C oral temperature cutoff, and 18 h
definition of prolonged membrane rupture. There
may be another risk factor for group B streptococcal
newborn infections. Two studies have shown a cor-
relation with the use of a fetal scalp electrode dur-
ing labor and the subsequent development of a
newborn group B streptococcal infection.53,54 Fur-
ther observations will be needed to fully determine
the risk of this invasive monitoring for newborn
group B streptococcal infection. With all of these
concerns, Figures 1 and 2 represent the current
standards for prevention for the obstetrician in the
United States.
We have two major reservations about the CDC
recommendations. They enforce a practice pattern
that may not pass the test of time. I have no doubt
these recommendations will increase the use of in-
trapartum antibiotics in the United States and de-
crease the number of group B streptococcal new-
born infections in the short run. Over the long
term, this strategy increases the risk of altering bac-
terial flora causing newborn disease. Surveillance
of the organisms causing newborn sepsis will be
necessary to detect this. These guidelines will also
limit the effectiveness of prospective studies trying
to pinpoint mothers at risk for having babies with
newborn disease and it will impede the study of
alternative approaches. For example, some obstet-
rical services in Europe use an antiseptic vaginal
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Risk factors:
Previous infant who had invasive GBS disease
GBS bacteriuria during this pregnancy
Delivery at < 37 weeks’ ,qestation*
NO
Collect rectal and vaginal swab for GBS culture
at 35-37 weeks’ gestation
Not done, incomplete,
or results unknown
GBS
negative
Risk factors:
Intrapartum temperature
>_ 100.4 F (>_ 38.0 C)
Membrane rupture 2 18 hours
No intrapartum prophylaxis needed
YES.
GBS
positive
YES,
Give intrapartum
penicillin
Offer intrapartum
penicillin
Give intrapartum
penicillint
If membrane ruptured at < 37 weeks’ gestation, and the mother has not begun labor, collect group B
streptococcal culture and either a) administer antibiotics until cultures are completed and the results are
negative or b) begin antibiotics only when positive cultures are available. No prophylaxis is needed if culture
obtained at 35-37 weeks’ gestation was negative.
t Broader spectrum antibiotics may be considered at the physician’s discretion, based on clinical
indications.
Fig. I. Algorithm for prevention of early onset of group B streptococcal (GBS) disease in neonates, using prenatal screening
at 35-37 weeks gestation.
lavage on all women admitted in labor and report a
remarkable decrease in group B streptococcal new-
born disease (Stray-Pederson, personal communi-
cation).
E. coli
E. coli is another pathogen of concern for obstetri-
cians in their quest to control newborn infections.
It is a frequent cause of newborn infection5s and on
most services ranks next to the group B streptococ-
cus in frequency. There are some aspects of E. coli
newborn infection that lend themselves to strate-
gies of control. Newborn infection results from ver-
tical transmission from the mother. Unlike the
group B streptococcus, maternal vaginal coloniza-
tion with E. coli seems to be a constant,s6 This
suggests that antepartum vaginal screening for this
organism could identify those women at risk. In
addition, specific strains of E. coli seem to have
more invasive properties and to be more dangerous
for newborns,s7 Again, identification screening
techniques could be employed to delineate women
at risk for infection. Intrapartum treatment should
be effective, but many E. coli strains are resistant to
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Are any of the following risk factors present?
Previously delivered infant who had invasive GBS disease
GBS bacteria during this pregnancy
Delivery at <37 weeks’ gestation
Duration of ruptured membranes > 18 hours
Intrapartum temperature > 100.4 F (> 38.0 C)
No intrapartum prophylaxis needed
Give
intrapartum
penicillint
If membrane ruptured at <37 weeks’ gestation, and the mother has not begun labor, collect group B
streptococcal culture and either a) administer antibiotics until cultures are completed and the results are
negative or b) begin antibiotics only when positive cultures are available.
t Broader spectrum antibiotics may be considered at the physician’s discretion, based on clinical
indications.
Fig. 2. Algorithm for prevention of early onset of group B streptococcal (GBS) disease in neonates, using risk factors.
ampicillin. Prospective studies need to be done to
determine the effectiveness of cephalosporins or
ampicillin with a beta lactamase inhibitor added.
H. influenzae
H. inf/uenzae is another important cause of newborn
infection,ss A current therapeutic problem is that
many strains ofH. influenzae are beta lactamase pro-
ducers and as such are resistant to ampicillin. Al-
ternative non-beta lactam antibiotics would be bet-
ter first-line agents in hospitals where ampicillin
resistant H. influenzae is a frequent finding.
U. urealyticum
U. urea/yticum remains an enigma. It is associated
with chronic lung disease in the premature new-
born.s9 The difficulty is that the majority of preg-
nant women are colonized with this organism
6 so
the problem of determining which newborn of
these colonized women will be at risk remains un-
solved. This organism has the potential to cause
problems. It can occasionally be isolated from the
amniotic fluid of women in premature labor.61 In
evaluating the pregnancy history of newborns who
become infected, the route of delivery did not alter
the risk of infection, but chorioamnionitis did.6z
The antibiotic of choice in the past has been eryth-
romycin, but administration of this drug to preg-
nant women was ineffective in reducing the num-
ber of women who remained vaginal culture posi-
tive for this organism.
6 Clearly, more studies will
be needed to delineate risk factors.
REFERENCES
1. CDC: Tetanus surveillancemUnited States, 1991-1994,
MMWR 46:15-25, 1997.
2. Harris RD, Rhoadcs EF: Varicella pneumonia compli-
cating pregnancy. Report of a case and review of the
literature. Obstet Gynecol 25:734-740, 1965.
3. Pastuszak AL, Levy M, Schick B, et al.: Outcome of the
maternal varicella infection in the first 20 weeks of preg-
nancy. N Engl J Med 330:901-905, 1994.
4. CDC: Increase in rubella and congenital rubella syn-
drome-United States, 1988-1990. 40:93-99, 1991.
5. Howson CP, Katz M, Johnson RB Jr, et al.: Chronic
arthritis after rubella vaccination. Clin Infect Dis 15:
307-312, 1992.
6. Stevens CE, Taylor PE, Tong MJ, et al.: Yeast-
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 173PREVENTION OF INFECTION IN PREGNANCY LEDGER AND SKUPSKI
recombinant-hepatitis B vaccine. JAMA 257:2612-2618,
1987.
7. Faro S: To vaccinate or not to vaccinate. Infect Dis
Obstet Gynecol 2:153, 1994.
8. Butler JC, Hofmann J, Catron MS, et al.: The continued
emergence of drug-resistant Streptococcus pneumoniae in
the United States, an update from the Centers for Dis-
ease Control and Prevention’s pneumonococcal sentinel
surveillance system. J Infect Dis 174:986-993, 1996.
9. American College of Obstetricians and Gynecologists:
Perinatal viral and parasitic infection. Tech Bull 177:1-
7, 1993.
10. Foulon W, Naessens A, Derde MD: Evaluation of the
possibilities for preventing congenital toxoplasmosis.
Am J Perinatol 11:57-62, 1994.
11. McCabe R, Remington JS: Toxoplasmosis: The time
has come. N Engl J Med 318:313-315, 1988.
12. Wilson CB, Remington JS: What can be done to prevent
congenital toxoplasmosis? Am J Obstet Gynecol 138:
357-363, 1980.
13. Kimball AC, Kean BH, Fuchs F: Congenital toxoplas-
mosis: A prospective study of 4,048 obstetric patients.
Am J Obstet Gynecol 111:211-218, 1971.
14. Guerina NG, Hsu H-W, Meissner C: Neonatal serologic
screening and early treatment for congenital Toxoplasma
gondil infection. N Engl J Med 330:1858-1863, 1994.
15. CDC: US PHS/IDSA guidelines for the prevention of
opportunistic infections in persons infected with human
immunodeficiency virus: A summary. MMWR 44:1-34,
1995.
16. Demmler GJ: Summary of a workshop on surveillance
for congenital cytomegalovirus disease. Rev Infect Dis
13:315-329, 1991.
17. Stagno S, Pass RE, Henderson RE, et al.: Congenital
cytomegalovirus infection. The relative importance of
primary and recurrent maternal infection. N Engl J Med
306:945-949, 1982.
18. Pass RE, Hutto C, Ricks R, et al.: Increased rate of
cytomegalovirus infection among parents of children at-
tending day care centers. N Engl J Med 314:1414-1418,
1986.
19. Gilbert GL, Hayes K, Hudson IL, et al.: Prevention of
transfusion-acquired cytomegalovirus infection in in-
fants by blood filtration to remove leukocytes. Lancet
1:1228-1231, 1989.
20. CDC: Update: Trends in AIDS incidence, deaths, and
prevalence--United States, 1996. MMWR 46:168-173,
1997.
21. Breining MK, Kingsley LA, Armstrong JA, et al.: Epi-
demiology of genital herpes in Pittsburgh: Serologic,
sexual and racial correlates of apparent and inapparent
herpes simplex infections. J Infect Dis 162:299-305,
1990.
22. Kulhanjian JA, Soroush V, Au DS, et al.: Identification
of women at unsuspected risk of primary infection with
herpes simplex virus type 2 during pregnancy. N Engl J
Med 326:916-920, 1992.
23. Brown ZA, Selke S, Zeh J, et al.: The acquisition of
herpes simplex virus during pregnancy. N Engl J Med
337:509-515, 1997.
24. Linnan MJ, Mascola L, Lou KD, et al.: Epidemic liste-
riosis associated with Mexican style cheese. N Engl J
Med 319:823-828, 1988.
25. Harris RE: The significance of eradication of bacteriuria
during pregnancy. Obstet Gynecol 53:71-73, 1979.
26. Hillier SL, Nugent RP, Eschenbach DA, et al.: Asso-
ciation between bacterial vaginosis and pre-term deliv-
ery of a low-birth-weight infant. N Engl J Med 333:
1737-1742, 1995.
27. McGregor JA, French JI, See K: Adjunctive clindamycin
therapy for preterm labor: Results of a double-blind,
placebo controlled trial. Am J Obstet Gynecol 165:867-
875, 1991.
28. Morales WJ, Schorr S, Albritton J: Effect of metronida-
zole in patients with preterm birth in preceding preg-
nancy and bacterial vaginosis: A placebo-controlled,
double blind study. Am J Obstet Gynecol 171:345-349,
1994.
29. McGregor JA, French JI, Jones W, et al.: Bacterial vag-
inosis is associated with prematurity and vaginal fluid
mucinase and sialidase: Results of a controlled trial of
topical clindamycin cream. Am J Obstet Gynecol 170:
1048-1060, 1994.
30. Joesoef MR, Hillier SL, Wiknjostro G, et al.: Intravagi-
nal clindamycin treatment for bacterial vaginosis: Ef-
fects on preterm delivery and low birth weight. Am
Obstet Gynecol 173:1527-1531, 1995.
31. Pastorek JG, Cotch MF, Martin DH, et al.: Clinical and
microbiological correlates of vaginal Trichomonas during
pregnancy. Clin Infect Dis 23:1075-1080, 1996.
32. Jeremias J, Draper D, Ziegert M, et al.: Detection of
Trichomonas vaginalis using the polymerasc chain reac-
tion in pregnant and non-pregnant women. Infect Dis
Obstet Gynecol 2:16-19, 1994.
33. Fouts AC, Kraus SJ: Trichomonas vaginalis: Re-
evaluation of its clinical presentation and laboratory di-
agnosis. Infect Dis 141:137-143, 1980.
34. Elliot B, Brunham RC, Laga M, et al.: Maternal gono-
coccal infection as a preventable risk factor for low birth
weight. J Infect Dis 161:531-536, 1990.
35. CDC: 1993 sexually transmitted diseases treatment
guidelines. MMWR 42:1-102, 1993.
36. Licciardi F, Grifo JA, Rosenwaks Z, et al.: Relation be-
tween antibodies to Chlamydia trachomatis and sponta-
neous abortion following in vitro fertilization. J Assist
Reprod Genet 9:207-210, 1992.
37. Alexander ER, Harrison HR: Role of Chlamydia tracho-
matis in perinatal infection. Rev Infect Dis 5:713-719,
1983.
38. Witkin SS, Jeremias J, Toth, et al.: Detection of Chla-
mydia trachomatis by the polymerase chain reaction in
the cervices of women with acute salpingitis. Am J Ob-
stet Gynecol 168:1438-1442, 1993.
39. Crombleholme WR, Schachter J, Grossman M, et al.:
Amoxicillin therapy for Chlamydia trachomatis in preg-
nancy. Obstet Gynecol 75:752-756, 1990.
40. Hammerschlag MR, Cummings C, Roblin PM, et al.:
174 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYPREVENTION OF INFECTION IN PREGNANCY LEDGER AND SKUPSKI
Efficacy of neonatal ocular prophylaxis for the preven-
tion of chlamydia and gonococcal conjunctivitis. N Engl
J Med 320:769-772, 1989.
41. Pyati SP, Plides RS, Jacobs NM, et al.: Penicillin in
infants weighing two kilograms or less with early onset
group B streptococcal disease. N Engl J Med 308:1383-
1389, 1983.
42. Yow MD, Mason EO, Leeds LJ, et al.: Ampicillin pre-
vents intrapartum transmission of group B streptococ-
cus. JAMA 241:1245-1247, 1979.
43. Lewin EB, Amstey MS: Natural history of group B
streptococcus colonization and its therapy during preg-
nancy. Am J Obstet Gynecol 139:512-515, 1981.
44. Skoll MA, Mercer BM, Baselski V, et al.: Evaluation of
two rapid group B streptococcal antigen tests in labor
and delivery patients. Obstet Gynecol 77:322-326,
1991.
45. Franciosi RA, Knostman JD, Zimmerman RA: Group B
streptococcal neonatal and infant infections. J Pediatr
82:707, 1973.
46. Baker CJ: Group B streptococcal infections in neonates.
Pediatr Rev 64:5, 1979.
47. Regan JA, Chao S, James LS: Premature rupture of
membranes, preterm delivery and group B streptococcal
colonization of mothers. Am J Obstet Gynecol 141:184-
186, 1981.
48. Klebanoff MA, Regan JA, Rao AV, et al.: Outcome of
the vaginal infections and prematurity study: Results of
a clinical trial of erythromycin among pregnant women
colonized with group B streptococci. Am J Obstet Gy-
nccol 172:1540-1545, 1995.
49. Hall RL, Barnes W, Krishnan L, et al.: Antibiotic treat-
ment of parturient women colonized with group B strep-
tococci. Am Obstet Gynecol 124:630-634, 1976.
50. CDC: Prevention of perinatal group B streptococcal dis-
ease: A public health perspective. MMWR 45:1-24,
1996.
51. McDuffie RS, McGregor JA, Gibbs RS: Adverse prena-
tal outcome and resistant Entro bactriacase after antibi-
otic usage for premature rupture of membranes and
group B streptococcus carriage. Obstet Gynecol 22:487-
489, 1993.
52. Rouse DJ, Goldenberg RL, Cliver SP, et al.: Strategies
for the prevention of early onset neonatal group B strep-
tococcal sepsis: A decision analysis. Obstet Gynecol 83:
483-494, 1994.
53. Bobitt JR, Ledger WJ: Obstetric observations in eleven
cases of neonatal sepsis due to the group B beta hemo-
lytic streptococcus. Obstet Gynecol 47:439-442, 1976.
54. Gill P, Sobeck J, Jarjoura D, et al.: Mortality from early
onset neonatal group B streptococcal sepsis: Influence
of obstetric factors. J Mat Fet Med 6:35-39, 1997.
55. Gladstone IM, Ehren Kranz RA, Edberg SC, et al.: A
ten year review of neonatal sepsis and comparison with
previous fifty year experience. Pcdiatr Infect Dis J 9:
819-825, 1990.
56. Amstey MS, Lewin E, Colaice J: Vaginal colonization
with invasive Escherichia coli during pregnancy. Am J
Obstet Gynecol 137:534-535, 1980.
57. Robbins JB, McCracken GH, Gotschlick EC, et al.:
Escherichia coli K. capsular polysaccharide associated
with neonatal meningitis. N Engl J Med 290:1216, 1974.
58. Rusin P, Adam RD, Petersen EA, et al.: Hemophilus
influenzae: An important cause of maternal and neonatal
infections. Obstet Gynecol 77:92-96, 1991.
59. Payne NR, Steinberg SS, Acherman P, et al.: New pro-
spective studies of the association of Ureaplasma urea-
lyticum colonization and chronic lung disease. Clin In-
fect Dis 17:Sl17-S121, 1993.
60. Eschenbach DA, Nugent RP, Rao AV, et al.: A random-
ized placebo controlled trial of erythromycin for the
treatment of Ureaplasma urealyticum to prevent prema-
ture delivery. Am J Obstet Gynecol 164:734-742, 1991.
61. Eschenbach DA: Ureaplasma urealyticum and premature
birth. Clin Infect Dis 17:S100-S106, 1993.
62. Sanchez PJ: Perinatal transmission of Ureaplasma urea-
lyticum: Current concepts based on review of the litera-
ture. Clin Infect Dis 17:S107-Sl11, 1993.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 175